Respironics' I-neb drug delivery tech:
This article was originally published in Clinica
Respironics has received US FDA 50(k) market clearance to use its third generation adaptive aerosol delivery (AAD) system for the aerosolisation of liquid medication approved for use with the product. The I-neb AAD inhalation technology continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. It is smaller, quieter and more portable than the firm's previous generation products. Murrysville, Pennsylvania-based Respironics said that I-neb's first application in the US will be at the end of 2005, through biopharmaceutical company CoTherix, which earlier this year received FDA go-ahead to use I-neb as a means of delivering its Ventavis (iloprost) inhalation solution for treating pulmonary arterial hypertension.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.